Key Findings: Participants: 338 obese adults Duration: 48 weeks Average weight loss: 17.5% to 24.2% depending on dose Metabolic improvements: Better insulin sensitivity, reduced inflammation markers These results put Retatrutide ahead of many current obesity drugs, making it one of the most promising new weight loss peptides of 2025
GLP-1 receptor agonism in heart failure Clinical evidence Only a few clinical investigations studying the effects of GLP-1 RAs specifically in HF (all in HFrEF) have been reported as briefly discussed below
The Wolverine Stack combines BPC-157 with TB-500, a second peptide that supports cell migration and systemic tissue regeneration
Interestingly, an infant's need for vitamin C is comparable to that of teenagers
Direct Meds prices their sublingual semaglutide at approximately $249 per month, making it their most affordable option
We recruited 28 patients with stable schizophrenia and 45 healthy participants matched for age, gender, and parental socio-economic status